Opinion|Videos|January 19, 2026
Other Standout Data in PTCL From ASH 2025
Author(s)Francine Foss, MD, Matthew Lunning, DO, FACP
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.
Advertisement
Episodes in this series
Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight additional notable peripheral T-cell lymphoma (PTCL) data presented at the 2025 ASH Annual Meeting and Exposition. They discuss emerging agents, novel combinations, and ongoing trials with potential clinical relevance. Foss and Lunning conclude by outlining key research directions to watch as the PTCL treatment landscape continues to evolve.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5